Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -67.99M | -58.82M | -72.55M | -58.70M | -53.72M |
| Total Depreciation and Amortization | 157.00K | 157.00K | 156.00K | 160.00K | 158.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.91M | 9.68M | 9.47M | 11.42M | 7.02M |
| Change in Net Operating Assets | -525.00K | -1.36M | 29.43M | -9.03M | 3.59M |
| Cash from Operations | -59.45M | -50.34M | -33.48M | -56.16M | -42.96M |
| Capital Expenditure | -- | 775.00K | 0.00 | 0.00 | -775.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.16M | -99.57M | 156.99M | 21.26M | -149.23M |
| Cash from Investing | 44.16M | -98.80M | 156.99M | 21.26M | -150.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 15.35M | 1.76M | 2.65M | 1.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 225.00K | -225.00K | -- | -- |
| Cash from Financing | -- | 15.57M | 1.53M | 2.65M | 1.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.29M | -133.57M | 125.04M | -32.25M | -191.11M |